Lotus Eye Hospital Institute Ltd vs Vaidya Sane Ayurved Laboratories Ltd Stock Comparison
Lotus Eye Hospital Institute Ltd vs Vaidya Sane Ayurved Laboratories Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Lotus Eye Hospital & Institute Ltd is ₹ 112.75 as of 23 Oct 15:30
. The P/E Ratio of Lotus Eye Hospital & Institute Ltd changed from 0 on March 2023 to 0 on March 2026 . This represents a CAGR of 0.0% over 4 yearsThe P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd changed from 51.1 on March 2023 to 19.5 on March 2026 . This represents a CAGR of -21.40% over 4 years The Market Cap of Lotus Eye Hospital & Institute Ltd changed from ₹ 0 crore on March 2023 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 4 yearsThe Market Cap of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 247.07 crore on March 2023 to ₹ 175.15 crore on March 2026 . This represents a CAGR of -8.24% over 4 years The revenue of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 17.27 crore as compare to the Mar '26 revenue of ₹ 14.09 crore. This represent the growth of 22.57% The revenue of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lotus Eye Hospital & Institute Ltd for the Jun '26 is ₹ 3.15 crore as compare to the Mar '26 ebitda of ₹ 0.95 crore. This represent the growth of 231.58% The ebitda of Vaidya Sane Ayurved Laboratories Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lotus Eye Hospital & Institute Ltd changed from ₹ 0.62 crore to ₹ 0.61 crore over 9 quarters. This represents a CAGR of -0.72%
The net profit of Vaidya Sane Ayurved Laboratories Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Lotus Eye Hospital & Institute Ltd changed from 66.24 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Vaidya Sane Ayurved Laboratories Ltd changed from 5.06 % on March 2023 to 0 % on March 2026 . This represents a CAGR of -100.00% over 4 years .
About Lotus Eye Hospital & Institute Ltd
Lotus Eye Hospital & Institute Limited, a trust hospital, was originally incorporated as 'Kalaivani Health Centre Pvt.
Limited' on 14 March, 1997.
The name of the Company was changed to 'Lotus Eye Care Hospital Pvt.
Limited' on 23 January, 2006 and later on, the Company was converted into a Public Limited Company on October 16, 2007 and subsequently, the name was changed to Lotus Eye Hospital & Institute Limited on April 12, 2013.
Founded in 1990 by renowned ophthalmic surgeon late Dr. S.K. Sundaramoorthy, the Company operates 9 Eye Care centers in Tamil Nadu and Kerala: 7 Centres in Tamil Nadu: Coimbatore (Peelamedu, RS puramand Saravanampatti), Salem , Tirupur Mettupalayam and Karur. 2 Centresin Kerala: Kochi and Mulanthuruthy.
Lotus Eye Care Hospital is the state of art eye care hospital group functioning in South India with specialization in super-specialty service related to eye care.
About Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'.
Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'.
A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune.
The Company is a unique medical service institution to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda.
Its approach to treatment using non-invasive, multidisciplinary and innovative therapies has helped the Company for treating the chronic ailments.
FAQs for the comparison of Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd
Which company has a larger market capitalization, Lotus Eye Hospital & Institute Ltd or Vaidya Sane Ayurved Laboratories Ltd?
Market cap of Lotus Eye Hospital & Institute Ltd is 234 Cr while Market cap of Vaidya Sane Ayurved Laboratories Ltd is 153 Cr
What are the key factors driving the stock performance of Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd?
The stock performance of Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd?
As of October 25, 2026, the Lotus Eye Hospital & Institute Ltd stock price is INR ₹112.75. On the other hand, Vaidya Sane Ayurved Laboratories Ltd stock price is INR ₹146.45.
How do dividend payouts of Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd compare?
To compare the dividend payouts of Lotus Eye Hospital & Institute Ltd and Vaidya Sane Ayurved Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.